＜＜Back

Next＞＞

Vol. 35　Suppl. 3　2007

Opening Remarks

H. Kawasaki

Jpn Pharmacol Ther 2007　35(s3) s173

---

1．Involvement of OATP family transporters in the hepatic uptake of bosentan, an endothelin receptor antagonist

K. Kubo, et al．

Jpn Pharmacol Ther 2007　35(s3) s179

---

2．The identification of transporters involved in hepatic transport of antihistamine drug, fexofenadine

K. Maeda, et al．

Jpn Pharmacol Ther 2007　35(s3) s185

---

3．4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and PFIC2-type mutated BSEP

H. Hayashi, et al．

Jpn Pharmacol Ther 2007　35(s3) s193

---

4．Importance of sinusoidal efflux mediated by Mrp3

Y. Kitamura, et al．

Jpn Pharmacol Ther 2007　35(s3) s197

---

5．Prediction and analysis of human pharmacokinetics based on physiologically based pharmacokinetic modeling including transporter-mediated membrane transport processes

T. Watanabe, et al．

Jpn Pharmacol Ther 2007　35(s3) s203

---

【Discussion 1～5】

Jpn Pharmacol Ther 2007　35(s3) s207

---

6．Glucuronidation of deoxycholic acid in the rat

M. Mikami, et al．

Jpn Pharmacol Ther 2007　35(s3) s213

---

7．Influence of elevation of γ-glutamyl transpeptidase by cholestatic liver disease on bone destruction

Y. Kawazoe, et al．

Jpn Pharmacol Ther 2007　35(s3) s215

---

8．The time course of the extracellular matrix related gene expression in rats with bile duct ligation

T. Sugihara, et al．

Jpn Pharmacol Ther 2007　35(s3) s219

---

9．A translational study of anti-angiogenic chemopreventive therapy using combination of vitamin K₂ and ACE inhibitor

H. Yoshiji, et al．

Jpn Pharmacol Ther 2007　35(s3) s225

---

【Discussion 6～9】

Jpn Pharmacol Ther 2007　35(s3) s231

---

10．The attack and prophylaxis on various porphyria by oxidative stress function and urinary porphyrin concentration

M. Aminaka, et al．

Jpn Pharmacol Ther 2007　35(s3) s235

---

11．Molecular defects in the protoporphyrinogen oxidase gene in Japanese patients with variegate porphyria

N. Maeda, et al．

Jpn Pharmacol Ther 2007　35(s3) s241

---

12．The association of MMP-2 gene polymorphisms with the progression of liver fibrosis in comparison with MMP-9

H. Ohtani, et al．

Jpn Pharmacol Ther 2007　35(s3) s247

---

【Discussion 10～12】

Jpn Pharmacol Ther 2007　35(s3) s247

---

13．Drug－induced liver injury was ameliorated in diabetic KK-A^y mice

K. Kon, et al．

Jpn Pharmacol Ther 2007　35(s3) s253

---

14．Angiotensin II type 1 receptor is associated with lipid accumulation in the liver

Y. Nabeshima, et al．

Jpn Pharmacol Ther 2007　35(s3) s257

---

15．A study of possible involvement of neovascularization of hepatic fibrogenesis in non-alcoholic steatohepatitis
―Basic and clinical studies―

M. Kitade, et al．

Jpn Pharmacol Ther 2007　35(s3) s261

---

【Discussion 13～15】

Jpn Pharmacol Ther 2007　35(s3) s267

---

16．Follow-up of patients with NASH by nuclear medicine tests

C. Koreeda, et al．

Jpn Pharmacol Ther 2007　35(s3) s271

---

17．Iron accumulation and phlebotomy in nonalcoholic fatty liver disease（NAFLD）

Y. Sumida, et al．

Jpn Pharmacol Ther 2007　35(s3) s277

---

18．Drug therapies for nonalcoholic steatohepatitis

H. Hyogo, et al．

Jpn Pharmacol Ther 2007　35(s3) s283

---

【Discussion 16～18】

Jpn Pharmacol Ther 2007　35(s3) s287

---

20．Insulin resistance induced by visceral obesity in patients with chronic hepatitis C

Y. Eguchi, et al．

Jpn Pharmacol Ther 2007　35(s3) s291

---

21．Body fat distribution in nonalcoholic fatty liver disease

M. Koda, et al．

Jpn Pharmacol Ther 2007　35(s3) s173

---

【Discussion 19～21】

Jpn Pharmacol Ther 2007　35(s3) s299

---

Closing Remarks

S. Kawata　

Jpn Pharmacol Ther 2007　35(s3) s303